Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
EUCRW was delisted on the 26th of April, 2023.
15 hedge funds and large institutions have $2.27M invested in Eucrates Biomedical Acquisition Corp. Warrant in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$500K |
| 2 |
6CM
683 Capital Management
New York
|
+$324K |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$216K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$192K |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$162K |
Top Sellers
EUCRW Hedge Fund Activity: Q1 2021 in Review
15 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q1 2021, worth a combined $2.27M.
Buyers outnumbered sellers: 15 funds opened new EUCRW positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $500K.
- 15 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $2.27M of Eucrates Biomedical Acquisition Corp. Warrant stock for Q1 2021.
- 15 funds opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q1 2021 and 0 closed out, a net change of +15 holders.
- The largest Eucrates Biomedical Acquisition Corp. Warrant buyer in Q1 2021 was BlackRock, an estimated $500K added.
Based on aggregated 13F filings for Q1 2021.